Search

Your search keyword '"Lunning, Matthew A."' showing total 748 results
Start Over Author "Lunning, Matthew A."
748 results on '"Lunning, Matthew A."'

1. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion

Author

Watt, Kymberly D., Rolak, Stacey, Foley, David P., Plichta, Jennifer K., Pruthi, Sandhya, Farr, Deborah, Zwald, Fiona O., Carvajal, Richard D., Dudek, Arkadiusz Z., Sanger, Cristina B., Rocco, Ricciardi, Chang, George J., Dizon, Don S., Langstraat, Carrie L., Teoh, Deanna, Agarwal, Piyush K., Al-Qaoud, Talal, Eggener, Scott, Kennedy, Cassie C., D’Cunha, Jonathan, Mohindra, Nisha A., Stewart, Shelby, Habermann, Thomas H., Schuster, Stephen, Lunning, Matthew, Shah, Nirav N., Gertz, Morie A., Mehta, Jayesh, Suvannasankha, Attaya, Verna, Elizabeth, Farr, Maryjane, Blosser, Christopher D, Hammel, Laura, and Al-Adra, David P.

Published
2024
Full Text
View/download PDF

2. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

Author

Vose, Julie M., Fu, Kai, Wang, Lu, Mansoor, Adnan, Stewart, Douglas, Cheng, Hongxia, Smith, Lynette, Yuan, Ji, Qureishi, Hina Naushad, Link, Brian K., Cessna, Melissa H., Barr, Paul M., Kahl, Brad S., Mckinney, Matthew S., Khan, Nadia, Advani, Ranjana H., Martin, Peter, Goy, Andre H., Phillips, Tycel J., Mehta, Amitkumar, Kamdar, Manali, Crump, Michael, Pro, Barbara, Flowers, Christopher R., Jacobson, Caron A., Smith, Sonali M., Stephens, Deborah M., Bachanova, Veronika, Jin, Zhaohui, Wu, Shishou, Hernandez-Ilizaliturri, Francisco, Torka, Pallawi, Anampa-Guzmán, Andrea, Kashef, Farshid, Li, Xing, Sharma, Sunandini, Greiner, Timothy C., Armitage, James O., Lunning, Matthew, Weisenburger, Dennis D., Bociek, Robert G., Iqbal, Javeed, Yu, Guohua, and Bi, Chengfeng

Published
2023
Full Text
View/download PDF

3. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Author

Jain, Michael D., Jacobs, Miriam T., Gao, Feng, Nastoupil, Loretta J., Spiegel, Jay Y., Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R., Goy, Andre, Hill, Brian T., Andreadis, Charalambos, Munoz, Javier, Chavez, Julio C, Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David, Neelapu, Sattva S., Locke, Frederick L., and Ghobadi, Armin

Published
2024
Full Text
View/download PDF

5. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Author

Nastoupil, Loretta J, Jain, Michael D, Feng, Lei, Spiegel, Jay Y, Ghobadi, Armin, Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick, Oluwole, Olalekan, McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison R, Goy, Andre, Hill, Brian T, Vu, Khoan, Andreadis, Charalambos, Munoz, Javier, Westin, Jason, Chavez, Julio C, Cashen, Amanda, Bennani, N Nora, Rapoport, Aaron P, Vose, Julie M, Miklos, David B, Neelapu, Sattva S, and Locke, Frederick L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Hematology, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antigens, CD19, Biological Products, Clinical Trials, Phase II as Topic, Comorbidity, Cytokine Release Syndrome, Female, Humans, Immunotherapy, Adoptive, L-Lactate Dehydrogenase, Leukapheresis, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Organizational Policy, Patient Selection, Progression-Free Survival, Recurrence, Retrospective Studies, Severity of Illness Index, Standard of Care, Survival Rate, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeAxicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed best overall and complete response rates in infused patients of 83% and 58%, respectively. We report clinical outcomes with axi-cel in the standard-of-care (SOC) setting for the approved indication.Patients and methodsData were collected retrospectively from all patients with relapsed/refractory LBCL who underwent leukapheresis as of September 30, 2018, at 17 US institutions with the intent to receive SOC axi-cel. Toxicities were graded and managed according to each institution's guidelines. Responses were assessed as per Lugano 2014 classification.ResultsOf 298 patients who underwent leukapheresis, 275 (92%) received axi-cel therapy. Compared with the registrational ZUMA-1 trial, 129 patients (43%) in this SOC study would not have met ZUMA-1 eligibility criteria because of comorbidities at the time of leukapheresis. Among the axi-cel-treated patients, grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 7% and 31%, respectively. Nonrelapse mortality was 4.4%. Best overall and complete response rates in infused patients were 82% (95% CI, 77% to 86%) and 64% (95% CI, 58% to 69%), respectively. At a median follow-up of 12.9 months from the time of CAR T-cell infusion, median progression-free survival was 8.3 months (95% CI, 6.0 to15.1 months), and median overall survival was not reached. Patients with poor Eastern Cooperative Oncology Group performance status of 2-4 and elevated lactate dehydrogenase had shorter progression-free and overall survival on univariable and multivariable analysis.ConclusionThe safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.

Published
2020

6. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.

Author

Chari, Ajai, Cornell, Robert, Gasparetto, Cristina, Karanes, Chatchada, Matous, Jeffrey, Niesvizky, Ruben, Lunning, Matthew, Usmani, Saad, Anderson, Larry, Chhabra, Saurabh, Girnius, Saulius, Shustik, Chaim, Stuart, Robert, Lee, Yihua, Salman, Zeena, Liu, Emily, and Valent, Jason

Subjects
Brutons tyrosine kinase inhibitor, carfilzomib, ibrutinib, multiple myeloma, Adenine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Oligopeptides, Piperidines, Prognosis, Pyrazoles, Pyrimidines, Salvage Therapy, Survival Rate
Abstract

Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed. Ibrutinib is a first-in-class, once-daily inhibitor of Brutons tyrosine kinase, an enzyme implicated in growth and survival of MM cells. Preclinical data suggest supra-additivity or synergy between ibrutinib and proteasome inhibitors (PIs) against MM. This phase 1/2b study evaluated the efficacy and safety of ibrutinib plus the PI carfilzomib and dexamethasone in patients with relapsed/refractory MM (RRMM). In this final analysis, we report results in patients who received the recommended phase 2 dose (RP2D; ibrutinib 840 mg and carfilzomib 36 mg/m2 with dexamethasone), which was determined in phase 1. The primary efficacy endpoint was overall response rate (ORR). Fifty-nine patients with RRMM received the RP2D (18 in phase 1 and 41 in phase 2b). These patients had received a median of three prior lines of therapy; 69% were refractory to bortezomib, and 90% were refractory to their last treatment. ORR in the RP2D population was 71% (stringent complete response and complete response: 3% each). Median duration of clinical benefit and median duration of response were both 6.5 months. Median progression-free survival (PFS) was 7.4 months, and median overall survival (OS) was 35.9 months. High-risk patients had comparable ORR and median PFS (67% and 7.7 months, respectively) to non-high-risk patients, whose ORR was 73% and median PFS was 6.9 months, whereas median OS in high-risk patients was 13.9 months and not reached in non-high-risk patients. The most common grade ≥3 hematologic treatment-emergent adverse events (TEAEs) were anemia and thrombocytopenia (17% each); the most common grade ≥3 non-hematologic TEAE was hypertension (19%). In patients with RRMM treated with multiple previous lines of therapy, ibrutinib plus carfilzomib demonstrated anticancer activity within the expected efficacy range. No new safety signals were identified and the combination was well-tolerated.

Published
2020

8. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Author

Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, and Kamdar, Manali

Published
2023
Full Text
View/download PDF

10. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Author

Jacobs, Miriam T., Jain, Michael D., Gao, Feng, Nastoupil, Loretta J., Spiegel, Jay Y., Lin, Yi, Dahiya, Saurabh, Lunning, Matthew, Lekakis, Lazaros, Reagan, Patrick M., Oluwole, Olalekan O., McGuirk, Joseph, Deol, Abhinav, Sehgal, Alison, Goy, Andre, Hill, Brian T., Andreadis, Charalambos, Munoz, Javier, Chavez, Julio C., Bennani, N. Nora, Rapoport, Aaron P., Vose, Julie M., Miklos, David B., Neelapu, Sattva S., Ghobadi, Armin, and Locke, Frederick L.

Published
2022
Full Text
View/download PDF

11. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Author

Kamdar, Manali, Solomon, Scott R, Arnason, Jon, Johnston, Patrick B, Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Maloney, David G, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Stepan, Lara, Ogasawara, Ken, Mack, Timothy, and Abramson, Jeremy S

Published
2022
Full Text
View/download PDF

12. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

13. Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL

Author

Al-Kadhimi, Zaid, Pirruccello, Samuel, Gul, Zartash, Maness-Harris, Lori, Bhatt, Vijaya Raj, Gundabolu, Krishna, Yuan, Jane, Lunning, Matthew, Bociek, Gregory, D’Angelo, Christopher, Kallam, Avyakta, Armitage, James, Abdullah, Khansa, Hunter, Angela, Mccaslin, Sarah, Lyden, Elizabeth, Smith, Lynnette, Callahan, II, Michael, Cole, Kathryn, Hinrichs, Steven, Talmadge, James, and Vose, Julie

Published
2022
Full Text
View/download PDF

17. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

18. Relapsed or Refractory Diffuse Large B-Cell Lymphoma: 'Dazed and Confused'

Author

Kesireddy, Meghana and Lunning, Matthew A.

Subjects
Care and treatment, Health aspects, Non-Hodgkin lymphomas -- Care and treatment, Mortality, Axicabtagene ciloleucel -- Health aspects, Chemotherapy -- Health aspects, Stem cells -- Health aspects, Drug approval -- Health aspects, Tisagenlecleucel -- Health aspects, T cells -- Health aspects, Non-Hodgkin's lymphomas -- Care and treatment, Cancer -- Chemotherapy
Abstract

Introduction Diffuse large B-cell lymphoma (DL-BCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and accounts for 30% to 40% of all NHL cases. The median age at diagnosis [...], Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Approximately 30% to 40% of patients will develop relapsed/refractory (R/R) DLBCL, leading to signifi cant morbidity and mortality. Salvage chemoimmunotherapy followed by high-dose chemotherapy and autologous stem cell rescue (HDT-ASCR) is the standard of care for chemosensitive and transplant-eligible R/R DLBCL. In patients who are ineligible for HDT-ASCR or who fail HDT-ASCR, treatment is mostly with palliative intent. However, the recent advances with chimeric antigen receptor T-cell (CAR-T) therapy and several FDA-approved targeted agents are changing the current landscape of R/R DLBCL management. There is no one-size-fi ts-all approach, and guidance regarding optimal sequencing of subsequent therapies is an unmet need. This review highlights the approved CAR-T constructs, including their effi cacy, adverse effects, and real-world data; bridging therapy to CAR-T; the role of emerging targeted agents, including bispecifi c antibodies; and the timing of these targeted agents in relation to CAR-T therapy. Providing individualized treatment with thoughtful sequencing of available agents is essential until future prospective randomized clinical trials provide more insights.

Published
2022

19. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

20. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Author

Evens, Andrew M., Danilov, Alexey, Jagadeesh, Deepa, Sperling, Amy, Kim, Seo-Hyun, Vaca, Ryan, Wei, Catherine, Rector, Daniel, Sundaram, Suchitra, Reddy, Nishitha, Lin, Yong, Farooq, Umar, D'Angelo, Christopher, Bond, David A., Berg, Stephanie, Churnetski, Michael C., Godara, Amandeep, Khan, Nadia, Choi, Yun Kyong, Yazdy, Maryam, Rabinovich, Emma, Varma, Gaurav, Karmali, Reem, Mian, Agrima, Savani, Malvi, Burkart, Madelyn, Martin, Peter, Ren, Albert, Chauhan, Ayushi, Diefenbach, Catherine, Straker-Edwards, Allandria, Klein, Andreas K., Blum, Kristie A., Boughan, Kirsten Marie, Smith, Scott E., Haverkos, Brad M., Orellana-Noia, Victor M., Kenkre, Vaishalee P., Zayac, Adam, Ramdial, Jeremy, Maliske, Seth M., Epperla, Narendranath, Venugopal, Parameswaran, Feldman, Tatyana A., Smith, Stephen D., Stadnik, Andrzej, David, Kevin A., Naik, Seema, Lossos, Izidore S., Lunning, Matthew A., Caimi, Paolo, Kamdar, Manali, Palmisiano, Neil, Bachanova, Veronika, Portell, Craig A., Phillips, Tycel, Olszewski, Adam J., and Alderuccio, Juan Pablo

Published
2021
Full Text
View/download PDF

21. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

Author

Ghione, Paola, Faruque, Promie, Mehta-Shah, Neha, Seshan, Venkatraman, Ozkaya, Neval, Bhaskar, Shakthi, Yeung, James, Spinner, Michael A., Lunning, Matthew, Inghirami, Giorgio, Moskowitz, Alison, Galasso, Natasha, Ganesan, Nivetha, van der Weyden, Carrie, Ruan, Jia, Prince, H. Miles, Trotman, Judith, Advani, Ranjana, Dogan, Ahmet, and Horwitz, Steven

Published
2020
Full Text
View/download PDF

22. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Author

Abramson, Jeremy S, Palomba, M Lia, Gordon, Leo I, Lunning, Matthew A, Wang, Michael, Arnason, Jon, Mehta, Amitkumar, Purev, Enkhtsetseg, Maloney, David G, Andreadis, Charalambos, Sehgal, Alison, Solomon, Scott R, Ghosh, Nilanjan, Albertson, Tina M, Garcia, Jacob, Kostic, Ana, Mallaney, Mary, Ogasawara, Ken, Newhall, Kathryn, Kim, Yeonhee, Li, Daniel, and Siddiqi, Tanya

Published
2020
Full Text
View/download PDF

23. Data from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

24. Table S2 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

25. Supplementary Methods from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

26. Figure S4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

27. FIGURE 3 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

28. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia

Author

Smith, Audrey L., primary, Skupa, Sydney A., additional, Eiken, Alexandria P., additional, Reznicek, Timothy E., additional, Schmitz, Elizabeth, additional, Williams, Nolan, additional, Moore, Dalia Y., additional, D’Angelo, Christopher R., additional, Kallam, Avyakta, additional, Lunning, Matthew A., additional, Bociek, R. Gregory, additional, Vose, Julie M., additional, Mohamed, Eslam, additional, Mahr, Anna R., additional, Denton, Paul W., additional, Powell, Ben, additional, Bollag, Gideon, additional, Rowley, M. Jordan, additional, and El-Gamal, Dalia, additional

Published
2024
Full Text
View/download PDF

29. FIGURE 4 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

30. FIGURE 5 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

31. FIGURE 1 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

32. FIGURE 6 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

33. FIGURE 2 from Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects

Author

Eiken, Alexandria P., primary, Smith, Audrey L., primary, Skupa, Sydney A., primary, Schmitz, Elizabeth, primary, Rana, Sandeep, primary, Singh, Sarbjit, primary, Kumar, Siddhartha, primary, Mallareddy, Jayapal Reddy, primary, de Cubas, Aguirre A, primary, Krishna, Akshay, primary, Kalluchi, Achyuth, primary, Rowley, M. Jordan, primary, D'Angelo, Christopher R., primary, Lunning, Matthew A., primary, Bociek, R. Gregory, primary, Vose, Julie M., primary, Natarajan, Amarnath, primary, and El-Gamal, Dalia, primary

Published
2024
Full Text
View/download PDF

35. Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects

Author

Eiken, Alexandria P, primary, Smith, Audrey L, additional, Skupa, Sydney A, additional, Schmitz, Elizabeth, additional, Rana, Sandeep, additional, Singh, Sarbjit, additional, Kumar, Siddhartha, additional, Mallareddy, Jayapal Reddy, additional, de Cubas, Aguirre A, additional, Krishna, Akshay, additional, Kalluchi, Achyuth, additional, Rowley, M. Jordan, additional, D'Angelo, Christopher R, additional, Lunning, Matthew A., additional, Bociek, R Gregory, additional, Vose, Julie M., additional, Natarajan, Amarnath, additional, and El-Gamal, Dalia, additional

Published
2024
Full Text
View/download PDF

36. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen

Author

Abramson, Jeremy S, primary, Solomon, Scott R, additional, Arnason, Jon, additional, Johnston, Patrick B, additional, Glass, Bertram, additional, Bachanova, Veronika, additional, Ibrahimi, Sami, additional, Mielke, Stephan, additional, Mutsaers, Pim, additional, Hernandez-Ilizaliturri, Francisco, additional, Izutsu, Koji, additional, Morschhauser, Franck, additional, Lunning, Matthew, additional, Crotta, Alessandro, additional, Montheard, Sandrine, additional, Previtali, Alessandro, additional, Ogasawara, Ken, additional, and Kamdar, Manali, additional

Published
2024
Full Text
View/download PDF

37. MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications

Author

Bi, Chengfeng, primary, Huang, Yuhua, additional, Ali, Roshia, additional, Wang, Fang, additional, Yang, Xia, additional, Bouska, Alyssa, additional, Xu, Lu, additional, Hao, Xinbao, additional, Lunning, Matthew A., additional, Chan, Wing C., additional, Iqbal, Javeed, additional, Weisenburger, Dennis D., additional, Vose, Julie M., additional, and Fu, Kai, additional

Published
2024
Full Text
View/download PDF

38. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy

Author

Lunning, Matthew A., primary, Wang, Hai‐lin, additional, Hu, Zhen‐Huan, additional, Locke, Frederick L., additional, Siddiqi, Tanya, additional, Jacobson, Caron A., additional, Ahmed, Sairah, additional, Miklos, David B., additional, Lin, Yi, additional, Hill, Brian T., additional, Ghobadi, Armin, additional, Neelapu, Sattva S., additional, Westin, Jason, additional, Dieyi, Chrisopher, additional, Field, Polly, additional, Miao, Harry, additional, Shahani, Shilpa A., additional, Patel, Anik, additional, Spooner, Clare, additional, Fu, Christine, additional, Muramoto, David, additional, Xu, Hairong, additional, and Pasquini, Marcelo C., additional

Published
2024
Full Text
View/download PDF

40. Contemporary Treatment Options Beyond Chimeric Antigen Receptor (CAR) T-Cell Therapies for Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): A Systematic Literature Review (SLR)

Author

Lunning, Matthew, primary, Dieyi, Christopher, additional, Field, Polly, additional, Hu, Zhen-Huan, additional, Radwan, Marta, additional, Miao, Harry, additional, Sun, Fang, additional, Fu, Christine, additional, Spooner, Clare, additional, and Pasquini, Marcelo C., additional

Published
2024
Full Text
View/download PDF

41. Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

Author

Palomba, M. Lia, primary, Siddiqi, Tanya, additional, Gordon, Leo I., additional, Kamdar, Manali, additional, Lunning, Matthew, additional, Hirayama, Alexandre V, additional, Abramson, Jeremy S., additional, Arnason, Jon, additional, Ghosh, Nilanjan, additional, Mehta, Amitkumar, additional, Andreadis, Charalambos, additional, Solomon, Scott R., additional, Kostic, Ana, additional, Singh, Ashvin, additional, Espinola, Ricardo, additional, Peng, Lily, additional, Ogasawara, Ken, additional, Chattin, Amy, additional, and Wang, Michael, additional

Published
2024
Full Text
View/download PDF

42. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy

Author

Crombie, Jennifer L., primary, Graff, Tara, additional, Falchi, Lorenzo, additional, Karimi, Yasmin H., additional, Bannerji, Rajat, additional, Nastoupil, Loretta J, additional, Thieblemont, Catherine, additional, Ursu, Renata, additional, Bartlett, Nancy L., additional, Nachar, Victoria R, additional, Weiss, Jonathan, additional, Osterson, Jane, additional, Patel, Krish, additional, Brody, Joshua D., additional, Abramson, Jeremy S, additional, Lunning, Matthew A, additional, Shah, Nirav N., additional, Ayed, Ayed, additional, Kamdar, Manali, additional, Parsons, Benjamin M., additional, Caimi, Paolo, additional, Flynn, Ian W., additional, Herrera, Alex F., additional, Sharman, Jeff P., additional, McKenna, Marshall, additional, Armand, Philippe, additional, Kahl, Brad S., additional, Smith, Sonali M, additional, Zelenetz, Andrew D, additional, Budde, Lihua E, additional, Hutchings, Martin, additional, Phillips, Tycel J., additional, and Dickinson, Michael, additional

Published
2024
Full Text
View/download PDF

43. Supplementary Table S4 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

44. Data from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

45. Supplementary Figure S2 from PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Author

Alderuccio, Juan Pablo, primary, Reis, Isildinha M., primary, Hamadani, Mehdi, primary, Nachiappan, Muthiah, primary, Leslom, Salman, primary, Kahl, Brad S., primary, Ai, Weiyun Z., primary, Radford, John, primary, Solh, Melhem, primary, Ardeshna, Kirit M., primary, Hess, Brian T., primary, Lunning, Matthew A., primary, Zinzani, Pier Luigi, primary, Stathis, Anastasios, primary, Carlo-Stella, Carmelo, primary, Lossos, Izidore S., primary, Caimi, Paolo F., primary, Han, Sunwoo, primary, Yang, Fei, primary, Kuker, Russ A., primary, and Moskowitz, Craig H., primary

Published
2024
Full Text
View/download PDF

46. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

Author

Nastoupil, Loretta J, Lunning, Matthew A, Vose, Julie M, Schreeder, Marshall T, Siddiqi, Tanya, Flowers, Christopher R, Cohen, Jonathon B, Burger, Jan A, Wierda, William G, O'Brien, Susan, Sportelli, Peter, Miskin, Hari P, Purdom, Michelle A, Weiss, Michael S, and Fowler, Nathan H

Published
2019
Full Text
View/download PDF

48. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study

Author

Wang, Michael, primary, Siddiqi, Tanya, additional, Gordon, Leo I., additional, Kamdar, Manali, additional, Lunning, Matthew, additional, Hirayama, Alexandre V., additional, Abramson, Jeremy S., additional, Arnason, Jon, additional, Ghosh, Nilanjan, additional, Mehta, Amitkumar, additional, Andreadis, Charalambos, additional, Solomon, Scott R., additional, Kostic, Ana, additional, Dehner, Christine, additional, Espinola, Ricardo, additional, Peng, Lily, additional, Ogasawara, Ken, additional, Chattin, Amy, additional, Eliason, Laurie, additional, and Palomba, M. Lia, additional

Published
2023
Full Text
View/download PDF

49. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

Author

Jacobson, Caron A., Locke, Frederick L., Ma, Long, Asubonteng, Julius, Hu, Zhen-Huan, Siddiqi, Tanya, Ahmed, Sairah, Ghobadi, Armin, Miklos, David Bernard, Lin, Yi, Perales, Miguel-Angel, Lunning, Matthew Alexander, Herr, Megan M., Hill, Brian T., Ganguly, Siddhartha, Dong, Hua, Nikiforow, Sarah, Hooper, Michele, Kawashima, Jun, Xu, Hairong, and Pasquini, Marcelo C.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results